Basic research for the development of peptide vaccination against Hepatitis C virus infection
丙型肝炎病毒感染肽疫苗开发的基础研究
基本信息
- 批准号:18590756
- 负责人:
- 金额:$ 2.57万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2006
- 资助国家:日本
- 起止时间:2006 至 2007
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Identification of CTL-epitope peptides: We selected and synthesized 44 9-mer or 10-mer peptides that were theoretically bind to HLA-A24 molecule from HCV1 b-derived protein by in silico analysis. We further picked up 6 peptides by patients' IgG antibody screening from the 44 peptides and CTL-inducing activity of the 6 peptides were subsequently examined using HCV-infected patients' peripheral blood mononuclear cells. Finally, we identified 3 peptides that are able to induce CTL in HLA-A24 patients (Hepatology Research, 2007). We also identified HLA-A3 supertype-restricted CTL-epitope peptides using similar strategy. Namely, we selected 46 peptides that were theoretically bind to HLA-A3 supertype (HLA-A3, -All, -A31, -A33) molecule from HCV1 b proteins by in silico analysis and finally 3 peptides that are able to induce CTL in HLA-A3 supertype patients were identified (Cancer Immunology Immunotherapy, 2007). The HLA-A2, -A24, and -A3 supertype are found in 40%, 60%, and 44%, respectivel … More y, of Japanese. Therefore, the previously identified vaccine candidate peptides for HLA-A2, together with the newly identified peptides for HLA-A24 and-A3 supertype patients, are able to cover the majority of HCV1 b patients in Japan.Anti-HCV peptide antibody as bio-marker: Relationship between serum IgG antibodies reactive to the CTL-epitope peptides and clinical status of HCV1 b-infected patients was analyzed. The serum IgG levels reactive to Core 35-44 peptide were found to correlate, with disease progression, such as progression from chronic hepatitis to liver cirrhosis or hepatocellular carcinoma. In contrast, the serum IgG levels to NS5A 2132-2142 peptide expressed reverse correlation to the disease progression (Med. Microbiol. Immunol., 2007).Clinical trial of peptide vaccination: To assess the safety and immune responses to a peptide vaccination of HCV1 b-derived peptides, 12 HCV1 b-positive patients, who were unresponsive to interferon-based therapy, were enrolled in the trial and safety and immunological effects of the vaccination were confirmed (Vaccine, 2007). Less
CTL表位肽的鉴定:我们通过计算机模拟分析,从HCV 1b衍生蛋白中选择并合成了44个理论上与HLA-A24分子结合的9-mer或10-mer肽。我们进一步通过患者的IgG抗体筛选从44种肽中挑选出6种肽,随后使用HCV感染患者的外周血单个核细胞检测6种肽的CTL诱导活性。最后,我们鉴定了能够在HLA-A24患者中诱导CTL的3种肽(Hepatology Research,2007)。我们还使用类似的策略鉴定了HLA-A3超型限制性CTL表位肽。即,我们通过计算机模拟分析从HCV 1 B蛋白中选择了理论上与HLA-A3超型(HLA-A3,-A11,-A31,-A33)分子结合的46种肽,并最终鉴定了能够在HLA-A3超型患者中诱导CTL的3种肽(Cancer Immunology Immunotherapy,2007)。HLA-A2、-A24和-A3超型分别占40%、60%和44%。 ...更多信息 ,日本人。因此,先前鉴定的HLA-A2的疫苗候选肽,连同新鉴定的HLA-A24和HLA-A3超型患者的肽,能够覆盖日本的大多数HCV 1 B患者。抗HCV肽抗体作为生物标志物:分析与CTL表位肽反应的血清IgG抗体与HCV 1 b感染患者的临床状态之间的关系。发现与核心35-44肽反应的血清IgG水平与疾病进展相关,例如从慢性肝炎进展为肝硬化或肝细胞癌。相比之下,针对NS 5A 2132-2142肽的血清IgG水平表达与疾病进展的负相关性(Med.Microbiol.免疫学,2007).肽疫苗接种的临床试验:为了评估对HCV 1b衍生肽的肽疫苗接种的安全性和免疫应答,将12名对基于干扰素的治疗无应答的HCV 1b阳性患者纳入试验,并证实了疫苗接种的安全性和免疫学效果(Vaccine,2007)。少
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Identification of hepatitis C virus (HCV) 2a-serived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-a24^+ and HCV2a-infected patients.
鉴定具有在人白细胞抗原-a24 和HCV2a感染的患者中诱导细胞毒性T淋巴细胞的能力的丙型肝炎病毒(HCV)2a-服务的表位肽。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Komohara Y;Yamada A;et. al.;Morimoto H;Y Wang.
- 通讯作者:Y Wang.
Serum levels of IgG to the peptide of HCV-1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at position 2132-2140 correlated with better prognosis in HCV-infected patients.
HCV-1b核心第35-44位肽的IgG水平与持续感染相关,而NS5A第2132-2140位肽的IgG水平与HCV感染患者更好的预后相关。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Takao Y;Itoh K;et al.
- 通讯作者:et al.
Phase 1 clinical study of a personalized peptide vaccination for patientsinfected with hepatitis C virus(HCV) lb who failed to respond to interferon-based therapy.
针对感染丙型肝炎病毒 (HCV) 1b 对干扰素治疗无反应的患者进行个性化肽疫苗接种的 1 期临床研究。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Yutani S;Yamada A;et. al.
- 通讯作者:et. al.
Serum levels pf IgG to the peptide of HCV-1b core at positions 35-44 correlated with persistent infection, while levels FIgG to the peptide of NS5A at position 2131-2140 correlated with better prognosis in HCV-infected patients.
HCV-1b核心35-44位的肽的血清IgG水平与持续感染相关,而NS5A 2131-2140位的肽的FIgG水平与HCV感染患者更好的预后相关。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:小林 聡;伊勢裕彦;他;Takao Y.
- 通讯作者:Takao Y.
Phase 1 clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy
针对感染丙型肝炎病毒 (HCV) 1b 且对干扰素治疗无反应的患者进行个性化肽疫苗接种的 1 期临床研究
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Yutani S;et. al.
- 通讯作者:et. al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YAMADA Akira其他文献
Randomized phase II trials of personalized peptide vaccination in advanced cancers
晚期癌症个性化肽疫苗接种的随机 II 期试验
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
ITO Kyogo;YUTANI Shigeru;SHICHIJO Sigeki;NOGUCHI Masanori;SASADA Tetsuro;YAMADA Akira;UEMURA Hirotsugu - 通讯作者:
UEMURA Hirotsugu
Quantitative Evaluation of Liver Function with Gd-EOB-DTPA-enhanced MR Imaging
Gd-EOB-DTPA 增强 MR 成像对肝功能的定量评估
- DOI:
10.2463/jjmrm.2019-1692 - 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Sayaka Misaki;Satoshi Murata;Miyuki Shimoji;Takayasu Iwai;Andreas Michael Sihombing;Ken Aoki;Yutaka Takahashi;Yoshiyuki Watanabe;北野瑞稀;YAMADA Akira - 通讯作者:
YAMADA Akira
YAMADA Akira的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YAMADA Akira', 18)}}的其他基金
Development of next generation transdermal vaccine for cancer treatment
开发用于癌症治疗的下一代透皮疫苗
- 批准号:
26430176 - 财政年份:2014
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of Novel Silicon Nanowire Array Solar Cells
新型硅纳米线阵列太阳能电池的开发
- 批准号:
24656203 - 财政年份:2012
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Evaluation of segmental liver reserve using functional imaging technique.
使用功能成像技术评估分段肝脏储备。
- 批准号:
23791405 - 财政年份:2011
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Basic research for the development of multi-peptide cocktail vaccines for cancer
癌症多肽鸡尾酒疫苗开发的基础研究
- 批准号:
23501292 - 财政年份:2011
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of high-efficiency Cu(InGa)Se2 thin-film solar cells fabricated by a nanoparticles based process
开发基于纳米颗粒的工艺制造的高效 Cu(InGa)Se2 薄膜太阳能电池
- 批准号:
22360006 - 财政年份:2010
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Study on the regulation of actomyosin interactions by twithcin
twithcin调节肌动球蛋白相互作用的研究
- 批准号:
22570167 - 财政年份:2010
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Visceral fat inspection method based on the ultrasound tomographic reconstruction of abdominal tissue sound speed image
基于腹部组织声速图像超声断层重建的内脏脂肪检查方法
- 批准号:
22560414 - 财政年份:2010
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Fundamental study for development of a peptide vaccine against hepatitis C virus
丙型肝炎病毒肽疫苗开发基础研究
- 批准号:
20590799 - 财政年份:2008
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Ultrasound Transmission Beam Computed Tomography for the In-situ Sound Speed Quantitative Diagnostic Imaging of Abdominal Tissue
超声透射束计算机断层扫描用于腹部组织原位声速定量诊断成像
- 批准号:
17560367 - 财政年份:2005
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new lung cancer antigens and development of peptide vaccine
肺癌新抗原的鉴定及肽疫苗的研制
- 批准号:
15590834 - 财政年份:2003
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Infectious Disease/Immunology Stimulating Access to Research in Residency (ID/IMM StARR) Program at Washington University
华盛顿大学传染病/免疫学促进住院医师研究 (ID/IMM StARR) 项目
- 批准号:
10592699 - 财政年份:2023
- 资助金额:
$ 2.57万 - 项目类别:
Cross-disciplinary Training in Immunology, Inflammation and Infectious Disease
免疫学、炎症和传染病的跨学科培训
- 批准号:
10413164 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别:
Cross-disciplinary Training in Immunology, Inflammation and Infectious Disease
免疫学、炎症和传染病的跨学科培训
- 批准号:
9761445 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别:
Cross-disciplinary Training in Immunology, Inflammation and Infectious Disease
免疫学、炎症和传染病的跨学科培训
- 批准号:
9923527 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别:
Cross-disciplinary Training in Immunology, Inflammation and Infectious Disease
免疫学、炎症和传染病的跨学科培训
- 批准号:
9572177 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别:
Cross-disciplinary Training in Immunology, Inflammation and Infectious Disease
免疫学、炎症和传染病的跨学科培训
- 批准号:
10715707 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别: